ClinicalTrials.gg
Active, not recruitingNCT06968585A166Updated May 8, 2026

A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy

A Phase 3 interventional study of A166 and T-DM1 in HER2-positive Breast Cancer, sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (part of Sichuan Kelun Pharmaceutical Co.,Ltd.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 9 months after the study started (first participant enrolled Jul 2023, registered Apr 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
365
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,928 studies in Breast Neoplasms with a site in China — 866 open to participants now, 1,064 under way, 210 of them phase 3. Breast Neoplasms · China.

Enrollment
330th of 1,519
365 · median 120
Started
2023
with 197 others
Phase 3
331 of 1,928
120 open now
Primary completion
2026-11
later than 499 of 1,063 live
Registered
1,543rd of 1,928
by date

Among the 1,928 studies in Breast Neoplasms with a site in China, this one is the 330th largest by enrollment of the 1,519 interventional ones that give a count, is one of 198 that started in 2023, is one of 331 in phase 3, reaches primary completion later than 499 of the 1,063 other live ones, and was the 1,543rd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

866 of the 1,928 studies in Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:

861 more — sign in →

All 866 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,928 studies in Breast Neoplasms with a site in China, or all of them as a file.
02

Study summary

Evaluation of the efficacy of A166 versus trastuzumab emtansine (T-DM1) in Patients with HER2-Positive unresectable or metastatic breast cancer previously treated with trastuzumab and taxane therapy

Read the detailed description

This study will evaluate the efficacy of A166 versus trastuzumab emtansine (T-DM1) in patients with HER2-positive unresectable or metastatic breast cancer previously treated with trastuzumab and taxane therapy

To further evaluate the efficacy of A166 versus T-DM1 in patients with HER2-positive unresectable or metastatic breast cancer, based on effectiveness endpoints including:

Overall survival (OS)

Progression-free survival (PFS) as assessed by investigators

Objective response rate (ORR), disease control rate (DCR), duration of response (DOR), and clinical benefit rate (CBR) assessed by both blinded independent central review (BICR) and investigators.

To assess the safety profile of A166 for injection in patients with HER2-positive unresectable or metastatic breast cancer.

To evaluate the immunogenicity of A166 for injection in patients with HER2-positive unresectable or metastatic breast cancer.

To characterize the pharmacokinetic (PK) profile of A166 for injection in patients with HER2-positive unresectable or metastatic breast cancer.

03

Conditions studied

  • HER2-positive Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patient ≥ 18 years and ≤ 75 years when signing the form.
  2. Breast cancer patients by histopathology and/or cytology documented.
  3. Disease progression after receiving a trastuzumab-based regimen (or a commercially available trastuzumab biosimilar or inetetamab) in the advanced or setting, or disease progression/recurrence within 12 months during or after (neo) therapy (with a trastuzumab-based regimen or commercially available trastuzumab biosimilar).
  4. Have previously received taxanes.
  5. Patients must have experienced disease progression or intolerance during or after the most recent treatment prior to randomization.
  6. At least one according to 1.1 criteria

Exclusion criteria

Exclusion Criteria:

  1. Previous treatment with A166 or any -targeted antibody-drug conjugate (ADC) with a microtubule inhibitor payload.
  2. Known history of severe to other monoclonal antibodies, or allergy to A166 , T-DM1 (trastuzumab emtansine) or their components.
  3. Permanent discontinuation of trastuzumab or its biosimilars due to any toxicity in prior treatments.
  4. Presence of severe corneal epithelial disease at baseline; or inability to perform daily activities without contact lenses.
  5. Presence of spinal cord compression or clinically active central nervous system (CNS) .
  6. Other conditions considered by the investigator to make the patient unsuitable for participation in the study
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
365 participants (actual)

Study arms

  • Experimental
    A166

    A166 is administered intravenously at a dose of 4.8 mg/kg every 21 (±3) days (q3w).

    Drug: A166

  • Active comparator
    T-DM1

    T-DM1 is administered intravenously at a dose of 3.6 mg/kg every 21 (±3) days (q3w).

    Drug: T-DM1

Interventions

  • DrugA166

    intravenous(IV) infusion (Q3W)

  • DrugT-DM1

    intravenous(IV) infusion (Q3W)

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS)

    PFS as assessed by BICR according to RECIST v 1.1

    Time frame: Randomization up to approximately 39 months

Secondary outcomes

  1. Overall survival (OS)

    OS, 1-year survival rate, 2-year survival rate, and 3-year survival rate.

    Time frame: Randomization up to approximately 48 months

  2. Objective response rate(ORR)

    ORR is defined as the percentage of patients who achieve complete response(CR) or partial response (PR), as assessed by BICR/investigator per RECIST 1.1

    Time frame: Randomization up to approximately 39 months

  3. Disease control rate(DCR)

    DCR is defined as the percentage of patients who achieve CR, PR or stable disease (SD), as assessed by BICR/investigator per RECIST 1.1

    Time frame: Randomization up to approximately 39 months

  4. Duration of response(DOR)

    DoR is defined as the time from the date of first documented CR or PR until date of documented disease progression per RECIST 1.1, as assessed by BICR/investigator or death due to any cause, whichever occurs first.

    Time frame: Randomization up to approximately 39 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Nov 2026, 40 months after the start.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 40 months is close to that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2025
First posted
May 13, 2025
StartActual
Jul 18, 2023
Primary completionEst.
Nov 30, 2026
CompletionEst.
Mar 31, 2028
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06968585
Responsible party
Sponsor
First posted
May 13, 2025
Start date
Jul 18, 2023
Primary completion
Nov 30, 2026 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
May 8, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab botidotin

Start the discussion